Shearman & Sterling represented BofA Merrill Lynch, Morgan Stanley, Barclays Capital and Deutsche Bank as joint book-running managers and representatives of the several managers in connection with Amgen’s offering of €550,000,000 4.375% Senior Notes due 2018 and £475,000,000 5.50% Senior Notes due 2026. The offering was conducted in accordance with Regulation S.
Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.
The following Shearman & Sterling team advised the managers in the transaction: partners John Wilson (San Francisco-Capital Markets), Lisa Jacobs (New York-Capital Markets) and Larry Crouch (Palo Alto-Tax); counsel Jung-Kyu McCann (Palo Alto-Capital Markets); and associates Phillip Monk (Palo Alto-Capital Markets), Christina Leto (London-Capital Markets) and Anil Kalia (Palo Alto-Tax).
Related Posts:
- Shearman & Sterling Advises on URS Corporation’s $1 Billion Offering of Senior Notes
- Shearman & Sterling Advises on Amgen Notes Offering
- Shearman & Sterling Advises Initial Purchasers in Broadcom’s $500 Million Offering of Senior Notes
- Shearman & Sterling Advises on Prospect Medical Holdings, Inc.’s $100 Million Senior Secured Notes Issuance and Consent Solicitation
- Shearman & Sterling Advises on Prospect Medical Holdings, Inc.’s Refinancing Transactions